Nervgen Pharma Corp Stock Today
| NGENF Stock | USD 2.00 0.13 6.95% |
Performance1 of 100
| Odds Of DistressOver 63
|
NervGen Pharma is trading at 2.00 as of the 29th of November 2024. This is a 6.95% increase since the beginning of the trading day. The stock's lowest day price was 1.87. NervGen Pharma has more than 63 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for NervGen Pharma Corp are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. The company has 58.68 M outstanding shares. More on NervGen Pharma Corp
Moving together with NervGen OTC Stock
Moving against NervGen OTC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
NervGen OTC Stock Highlights
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
NervGen Pharma Corp [NGENF] is traded as part of a regulated electronic over-the-counter service offered by the NASD. The company currently falls under 'Micro-Cap' category with a current market capitalization of 87.43 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NervGen Pharma's market, we take the total number of its shares issued and multiply it by NervGen Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. NervGen Pharma Corp classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 58.68 M outstanding shares.
NervGen Pharma Corp has accumulated about 11.65 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2.
Check NervGen Pharma Probability Of Bankruptcy
Ownership AllocationNervGen Pharma Corp maintains a total of 58.68 Million outstanding shares. NervGen Pharma Corp holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NervGen Ownership Details
NervGen Pharma Corp Risk Profiles
| Mean Deviation | 3.24 | |||
| Semi Deviation | 4.64 | |||
| Standard Deviation | 4.74 | |||
| Variance | 22.45 |
NervGen Stock Against Markets
Picking the right benchmark for NervGen Pharma otc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in NervGen Pharma otc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for NervGen Pharma is critical whether you are bullish or bearish towards NervGen Pharma Corp at a given time. Please also check how NervGen Pharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in NervGen Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Commodity Directory Now
Commodity DirectoryFind actively traded commodities issued by global exchanges |
| All Next | Launch Module |
NervGen Pharma Corporate Management
Elected by the shareholders, the NervGen Pharma's board of directors comprises two types of representatives: NervGen Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NervGen. The board's role is to monitor NervGen Pharma's management team and ensure that shareholders' interests are well served. NervGen Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NervGen Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian McAlister | CoFounder Advisor | Profile | |
| Harold DMD | CoFounder Director | Profile | |
| Adam MD | Interim Director | Profile | |
| William BASc | Interim CoFounder | Profile |
Other Information on Investing in NervGen OTC Stock
NervGen Pharma financial ratios help investors to determine whether NervGen OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NervGen with respect to the benefits of owning NervGen Pharma security.